The Bull Rankings scorecard — our quality-growth score is 75.3 / 100, built from three pillars scored 0–100: Quality 67, Growth 99, Value 65 (valuation is judged against sector peers). At today's price, our reverse-DCF read says the market is implicitly betting on free-cash-flow growth of about 42% a year next year, fading to 3% a year by year ten — a gauge of how much optimism is already in the stock.
The thesis
Alnylam’s numbers in the quarter ended 2026-06-30 are the kind of compounder sheet that makes analysts reach for superlatives—until the stock price is mentioned. Revenue grew 65.2% year over year, free cash flow hit $465 million, and return on equity sits at 54.1%. The market prices in a lot of that success, though less than the latest growth rate. Our model’s quality-growth score of 75.3/100, with Growth at 99 and Value at 65, tells the story: this is a high-quality compounder whose growth engine is firing on all cylinders, and the valuation pillar is the softest of the three, though still on the cheap side of peers. The reverse-DCF read of ~42% annual free-cash-flow growth (in year one, slowing to 3% a year by year ten) is the elephant in the room—it sits below the 65.2% revenue growth reported in the latest year, so the price assumes that growth cools. The market is pricing in a lot of success. That’s why the bull case must start with the Growth pillar, but the bear case can’t ignore how much success is already in the price.
What the business actually is
Alnylam turns RNA interference into blockbuster drugs. Its commercial lineup includes ONPATTRO for hereditary transthyretin-mediated amyloidosis, AMVUTTRA for the same disease with a newer formulation, Leqvio for hypercholesterolemia (sold by partner Novartis), Qfitlia for hemophilia A or B (sold by partner Sanofi), GIVLAARI for acute hepatic porphyria, and OXLUMO for primary hyperoxaluria type 1. The pipeline is deep, with Phase 3 programs like Nucresiran for ATTR amyloidosis and Zilebesiran for hypertension. The company isn’t just selling drugs; it’s selling a platform that can be tuned for multiple rare and common diseases, turning RNA interference from a scientific curiosity into a repeatable revenue engine. The growth in the latest year shows the platform is scaling—65.2% revenue growth isn’t a fluke when you’re expanding from rare diseases into larger indications like ATTR cardiomyopathy.
Why it can (or can't) keep compounding
The durability case rests on two pillars: returns and moat. ROE of 54.1% is the kind of number that usually belongs to tech monopolies, not biotech, and it signals that Alnylam is extracting value from its platform faster than it’s reinvesting. Profit margins of 19.7% prove the model works at scale. The moat is the RNA interference platform itself—once a drug like Leqvio is approved and embedded in treatment protocols, switching costs for patients and payers are high. Competitors can’t replicate the platform overnight; they’d need their own RNA interference programs, regulatory approvals, and payer relationships. Our model’s signal of diluting shareholders is the one caution flag: if dilution accelerates, it would erode the ROE advantage and signal that the company is funding growth with equity rather than cash flow. But for now, the platform’s flywheel is intact.
The valuation question
The market has priced in a future that assumes Alnylam can grow free cash flow ~42% next year, slowing to 3% a year by year ten, a starting rate that is still below the 65.2% revenue growth reported in the latest year. The P/E of 39.1 is high, but not absurd for a growth stock—and the implied growth rate, while high, trails the business’s own pace. The analyst consensus target of $372.29 sits in the middle of a wide range ($230–$536), reflecting deep disagreement about whether the stock is cheap at $224.60 or a value trap disguised as a compounder. The Value pillar in our model—65 versus the Growth pillar’s 99—is the softest of the three, though a 65 still sits on the cheap side of sector peers; the risk is that the downside is underappreciated. The stock’s 52-week range ($197.81–$495.55) tells the same story: buyers are betting on a rerating, while sellers see a business that’s already delivered most of its gains.
The bear case
The strongest skeptic’s argument is simple: the stock still discounts a lot of success. The reverse-DCF implied growth of ~42% is below the revenue growth the company just posted, and it fades toward 3% by year ten, so the price assumes that pace cools. The model’s signal of diluting shareholders is the canary in the coal mine—if dilution accelerates, it would confirm that the company is funding growth with equity rather than cash flow, a classic red flag for compounders. The Value pillar in our model—65—is the softest of the three, but it still sits on the cheap side of sector peers, so the valuation risk is less about multiples than about growth cooling.
What would change our mind
Two falsifiable conditions would flip the thesis. First, if free cash flow growth falls below 20% annually for two consecutive years, the growth story would crack, and the valuation would look indefensible. Second, if return on equity drops below 30%, the moat would erode, signaling that the platform’s advantages aren’t as durable as believed. Either development would force a reassessment of the quality-growth score and likely trigger a re-rating. Until then, the stock remains a high-wire act—impressive while it lasts, but not for the faint of heart.